Effect of Leflunomide on Pegloticase Response Rate in Patients with Uncontrolled Gout: A Retrospective Study.

Karim Richard MasriLissa Padnick-SilverKevin WinterlingBrian LaMoreaux

Published in: Rheumatology and therapy (2022)

This study supports leflunomide as co-therapy to pegloticase in uncontrolled gout patients. Heterogeneity and high comorbidity burden in uncontrolled gout patients makes having a variety of immunomodulators options important.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
prognostic factors
uric acid
peritoneal dialysis
mesenchymal stem cells